[go: up one dir, main page]

DK3205661T3 - Hsp70-afledt immunitetsinducerende peptid - Google Patents

Hsp70-afledt immunitetsinducerende peptid Download PDF

Info

Publication number
DK3205661T3
DK3205661T3 DK15849707.3T DK15849707T DK3205661T3 DK 3205661 T3 DK3205661 T3 DK 3205661T3 DK 15849707 T DK15849707 T DK 15849707T DK 3205661 T3 DK3205661 T3 DK 3205661T3
Authority
DK
Denmark
Prior art keywords
peptime
hsp70
inducing
derived immunity
immunity
Prior art date
Application number
DK15849707.3T
Other languages
English (en)
Inventor
Tomoya Miyakawa
Masaaki Oka
Shoichi Hazama
Koji Tamada
Keiko Udaka
Original Assignee
Cytlimic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytlimic Inc filed Critical Cytlimic Inc
Application granted granted Critical
Publication of DK3205661T3 publication Critical patent/DK3205661T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/19Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24Antigen-presenting cells [APC]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4262Heat shock proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53Liver

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK15849707.3T 2014-10-07 2015-10-07 Hsp70-afledt immunitetsinducerende peptid DK3205661T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014206730 2014-10-07
PCT/JP2015/078504 WO2016056596A1 (ja) 2014-10-07 2015-10-07 Hsp70由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法

Publications (1)

Publication Number Publication Date
DK3205661T3 true DK3205661T3 (da) 2021-08-02

Family

ID=55653202

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15849707.3T DK3205661T3 (da) 2014-10-07 2015-10-07 Hsp70-afledt immunitetsinducerende peptid

Country Status (12)

Country Link
US (3) US10537626B2 (da)
EP (2) EP3205661B1 (da)
JP (1) JP6423889B2 (da)
CN (1) CN107001418A (da)
AU (2) AU2015329070B2 (da)
BR (1) BR112017006969A2 (da)
CA (2) CA2963909C (da)
DK (1) DK3205661T3 (da)
ES (1) ES2882827T3 (da)
RU (1) RU2684911C2 (da)
TW (1) TWI687434B (da)
WO (1) WO2016056596A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017006969A2 (pt) 2014-10-07 2017-12-19 Cytlimic Inc peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
AU2016230125B2 (en) 2015-03-09 2020-07-16 Nec Corporation Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells
JP6311094B2 (ja) 2015-04-07 2018-04-18 サイトリミック株式会社 医薬
AU2017342189B2 (en) 2016-10-11 2023-09-21 Nec Corporation Medicine
WO2023163094A1 (ja) * 2022-02-25 2023-08-31 日本電気株式会社 成人t細胞白血病の治療又は予防のための医薬組成物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196523A (en) * 1985-01-01 1993-03-23 The University Of Southern California Control of gene expression by glucose, calcium and temperature
JPH08151396A (ja) 1994-11-28 1996-06-11 Teijin Ltd Hla結合性オリゴペプチド及びそれを含有する免疫調節剤
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
EP1303287A4 (en) * 2000-06-16 2006-02-08 Argonex Pharmaceuticals MHC PEPTIDES OVEREXPRESSED IN PROSTATE CANCER CELL AND METHODS FOR THEIR USE
ATE430161T1 (de) * 2000-09-13 2009-05-15 Multimmune Gmbh Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung
CN1555272A (zh) * 2001-07-31 2004-12-15 �ո��� 调节免疫应答的组合物和方法
JP4406607B2 (ja) 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 ペプチド及びこれを含む医薬
US7387271B2 (en) 2002-12-30 2008-06-17 3M Innovative Properties Company Immunostimulatory combinations
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
WO2006004182A1 (ja) 2004-07-07 2006-01-12 Nec Corporation 配列予測システム
US20090035330A1 (en) 2005-05-19 2009-02-05 Marianne Dewerchin Vaccine Composition Comprising B-Subunit Of E. coli Heat Toxin And An Antigen And An Adjuvant
PL1923463T3 (pl) 2005-08-09 2012-02-29 Oncotherapy Science Inc Peptyd antygenowy do odrzucania raka pochodzący z glipikan-3 (GPC3) do zastosowania u HLA-A2-pozytywnego pacjenta i środek farmaceutyczny zawierający antygen
US20100015101A1 (en) 2006-03-28 2010-01-21 Noriyuki Sato Novel tumor antigen peptides
RU2333767C2 (ru) 2006-03-31 2008-09-20 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Вакцинные композиции, способы их применения для профилактики и лечения меланомы и генетические конструкции для получения действующих компонентов композиции
CN101311270A (zh) 2006-08-18 2008-11-26 上海交通大学医学院 一种可诱生细胞免疫应答的真核表达载体及其疫苗
KR101454287B1 (ko) * 2006-10-17 2014-11-04 온코세라피 사이언스 가부시키가이샤 Mphosph1 또는 depdc1 폴리펩티드를 발현하는 암에 대한 펩티드 백신
WO2008106491A2 (en) * 2007-02-27 2008-09-04 University Of Utah Research Foundation Peptides that interact with topoisomerase i and methods thereof
JP2010532785A (ja) * 2007-07-06 2010-10-14 ウニベルジテイト・ウトレヒト・ホールディング・ビー.ブイ. 炎症性疾患および自己免疫疾患の治療および予防
WO2009036349A1 (en) 2007-09-12 2009-03-19 Anaphore, Inc. Hsp70-based treatment for autoimmune diseases
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물
WO2011017162A2 (en) * 2009-08-03 2011-02-10 The Johns Hopkins University Methods for enhancing antigen-specific immune responses
CA2777198C (en) 2009-10-06 2018-07-24 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer
WO2012139094A2 (en) 2011-04-08 2012-10-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of developing a vaccine using peptide-poly ic complexes
GB2512558A (en) 2012-02-02 2014-10-01 California Stem Cell Inc Pluripotent germ layer origin antigen presenting cancer vaccine
HK1204929A1 (en) * 2012-02-07 2015-12-11 La Jolla Institute For Allergy And Immunology Timothy grass allergens and methods and uses for immune response modulation
US20130217122A1 (en) 2012-02-21 2013-08-22 The Trustees Of The University Of Pennsylvania Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
WO2013143026A1 (en) 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑
CN103897047B (zh) * 2012-12-27 2016-01-20 中国科学院植物研究所 蛋白BhHSP70-1及其编码基因与应用
CA2902433A1 (en) 2013-03-01 2014-09-04 Astex Pharmaceuticals, Inc. Drug combinations
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
BR112017006969A2 (pt) 2014-10-07 2017-12-19 Cytlimic Inc peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
AU2016230125B2 (en) 2015-03-09 2020-07-16 Nec Corporation Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells
JP6311094B2 (ja) 2015-04-07 2018-04-18 サイトリミック株式会社 医薬

Also Published As

Publication number Publication date
US20180169199A1 (en) 2018-06-21
EP3925968A2 (en) 2021-12-22
RU2684911C2 (ru) 2019-04-16
JPWO2016056596A1 (ja) 2017-08-17
US11304997B2 (en) 2022-04-19
CN107001418A (zh) 2017-08-01
EP3205661A1 (en) 2017-08-16
US10537626B2 (en) 2020-01-21
WO2016056596A1 (ja) 2016-04-14
AU2018274976A1 (en) 2019-01-03
US12448413B2 (en) 2025-10-21
CA2963909C (en) 2021-06-15
CA2963909A1 (en) 2016-04-14
US20220193213A1 (en) 2022-06-23
US20200121772A1 (en) 2020-04-23
RU2017115719A (ru) 2018-11-14
TW201619190A (zh) 2016-06-01
AU2018274976B2 (en) 2019-05-02
EP3205661B1 (en) 2021-07-07
BR112017006969A2 (pt) 2017-12-19
CA3116265A1 (en) 2016-04-14
EP3205661A4 (en) 2018-08-08
JP6423889B2 (ja) 2018-11-14
AU2015329070B2 (en) 2018-11-22
EP3925968A3 (en) 2022-03-02
TWI687434B (zh) 2020-03-11
RU2017115719A3 (da) 2018-11-14
ES2882827T3 (es) 2021-12-02
AU2015329070A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
NO2025057I1 (no) epcoritamab
NO2023039I1 (no) Glofitamab
NL301167I2 (nl) Lumasiran
FIC20220017I1 (fi) Lonapegsomatropiini
DK3209778T3 (da) Kombination
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK4242916T3 (da) Forstøver
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3006072T3 (da) Karadgang
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
DK3222714T3 (da) Phytasemutanter
DK3119396T3 (da) Muscarinreceptoragonister
EP3230438C0 (en) N-GLYCOSYLATION
FR3024324B3 (fr) Souffleur
EP4011484C0 (en) CARBONIC ANHYDRASE OF THERMOVIBRIO AMMONIFICANS
DK3183340T3 (da) Termolabile exonukleaser
DE112015001664A5 (de) Betätigungsaktuator
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DK3122763T3 (da) Antimikrobielle peptiddendrimerer
DE112015005041A5 (de) Gargerätevorrichtung
DK3110439T3 (da) Pcsk9-vacciner
DE102014000623A8 (de) Halbhohlnietelement
DK3205661T3 (da) Hsp70-afledt immunitetsinducerende peptid
DK3009858T3 (da) Skyradar
DE202014005655U8 (de) llluminationsvorrichtung